Alnylam Pharmaceuticals, Inc. NASDAQ:ALNY

Alnylam Pharmaceuticals stock price today

$449.12
+211.15
+88.73%
Financial Health
0
1
2
3
4
5
6
7
8
9

Alnylam Pharmaceuticals stock price monthly change

-8.65%
month

Alnylam Pharmaceuticals stock price quarterly change

-8.65%
quarter

Alnylam Pharmaceuticals stock price yearly change

+21.06%
year

Alnylam Pharmaceuticals key metrics

Market Cap
30.89B
Enterprise value
25.45B
P/E
-20.76
EV/Sales
24.53
EV/EBITDA
-28.74
Price/Sales
24.09
Price/Book
-158.00
PEG ratio
0.71
EPS
-2.65
Revenue
2.00B
EBITDA
-195.38M
Income
-332.07M
Revenue Q/Q
54.82%
Revenue Y/Y
75.20%
Profit margin
-109.04%
Oper. margin
-75.68%
Gross margin
83.73%
EBIT margin
-75.68%
EBITDA margin
-9.75%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Alnylam Pharmaceuticals stock price history

Alnylam Pharmaceuticals stock forecast

Alnylam Pharmaceuticals financial statements

Average Price Target
Last Year

$329.83

Potential downside: -26.56%

Based on estimate of 5 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Profit margin
Jun 2023 318.75M -276.02M -86.59%
Sep 2023 750.53M 147.75M 19.69%
Dec 2023 439.71M -137.87M -31.35%
Mar 2024 494.33M -65.93M -13.34%
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Earnings per share (EPS)
2024-02-15 -1.2 -1.1
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Debt to assets
Jun 2023 3402396000 3.81B 112%
Sep 2023 3839073000 4.00B 104.32%
Dec 2023 3829880000 4.05B 105.76%
Mar 2024 3824386000 4.04B 105.73%
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Cash Flow
Jun 2023 -58.98M -8.71M 53.39M
Sep 2023 359.41M -10.76M 33.13M
Dec 2023 -29.79M -240.65M 39.22M
Mar 2024 -81.51M -67.62M 28.91M

Alnylam Pharmaceuticals alternative data

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Employee count
Aug 2023 2,002
Sep 2023 2,002
Oct 2023 2,002
Nov 2023 2,002
Dec 2023 2,002
Jan 2024 2,002
Feb 2024 2,002
Mar 2024 2,100
Apr 2024 2,100
May 2024 2,100
Jun 2024 2,100
Jul 2024 2,100

Alnylam Pharmaceuticals other data

94.77% +1.20%
of ALNY is owned by hedge funds
112.25M +781.37K
shares is hold by hedge funds

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Insider trades (number of shares)
Period Buy Sel
Feb 2024 0 46855
May 2024 0 21700
Jun 2024 0 55762
Jul 2024 0 7093
Aug 2024 0 72423
Nov 2024 0 13052
Dec 2024 0 1752
Transaction Date Insider Security Shares Price per share Total value Source
Sale
GARG PUSHKAL officer: CMO & EVP Dev & Med Af..
Common Stock 121 $247.48 $29,945
Sale
GARG PUSHKAL officer: CMO & EVP Dev & Med Af..
Common Stock 186 $248.99 $46,312
Sale
GARG PUSHKAL officer: CMO & EVP Dev & Med Af..
Common Stock 426 $250.08 $106,534
Sale
GARG PUSHKAL officer: CMO & EVP Dev & Med Af..
Common Stock 778 $251.68 $195,807
Sale
GARG PUSHKAL officer: CMO & EVP Dev & Med Af..
Common Stock 100 $252.94 $25,294
Sale
GARG PUSHKAL officer: CMO & EVP Dev & Med Af..
Common Stock 140 $254.37 $35,612
Sale
GARG PUSHKAL officer: CMO & EVP Dev & Med Af..
Common Stock 1 $255.8 $256
Sale
FITZGERALD KEVIN JOSEPH officer: CSO & EVP, Head of Res..
Common Stock 210 $250.45 $52,595
Sale
FITZGERALD KEVIN JOSEPH officer: CSO & EVP, Head of Res..
Common Stock 851 $251.98 $214,435
Sale
FITZGERALD KEVIN JOSEPH officer: CSO & EVP, Head of Res..
Common Stock 360 $253.44 $91,238
Patent
Application
Filling date: 28 Sep 2021 Issue date: 25 Aug 2022
Application
Filling date: 10 Aug 2021 Issue date: 18 Aug 2022
Application
Filling date: 26 Oct 2021 Issue date: 11 Aug 2022
Application
Filling date: 14 Sep 2021 Issue date: 11 Aug 2022
Grant
Filling date: 16 Apr 2020 Issue date: 9 Aug 2022
Application
Filling date: 14 Sep 2021 Issue date: 4 Aug 2022
Grant
Filling date: 12 Jan 2022 Issue date: 2 Aug 2022
Grant
Filling date: 25 Nov 2019 Issue date: 2 Aug 2022
Application
Filling date: 6 Apr 2022 Issue date: 28 Jul 2022
Application
Filling date: 31 Jan 2022 Issue date: 21 Jul 2022
Insider Compensation
Dr. John M. Maraganore M.D., Ph.D. (1963) Chief Executive Officer & Executive Director $2,070,000
Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB (1963) Pres, Chief Operating Officer & Director
$1,240,000
Dr. Akshay K. Vaishnaw (1963) Pres of R&D $1,090,000
Mr. Jeffrey V. Poulton M.B.A. (1968) Chief Financial Officer & Executive Vice President
$893,470
Mr. Michael W. Bonney B.A. (1958) Executive Chairman
$106,250
Wednesday, 25 December 2024
zacks.com
Thursday, 19 December 2024
zacks.com
Wednesday, 4 December 2024
zacks.com
Wednesday, 27 November 2024
businesswire.com
Tuesday, 26 November 2024
zacks.com
Monday, 25 November 2024
businesswire.com
Monday, 18 November 2024
zacks.com
Sunday, 17 November 2024
businesswire.com
Monday, 11 November 2024
https://thefly.com
Monday, 4 November 2024
businesswire.com
Friday, 1 November 2024
zacks.com
Thursday, 31 October 2024
seekingalpha.com
zacks.com
zacks.com
businesswire.com
Monday, 28 October 2024
zacks.com
Sunday, 27 October 2024
seekingalpha.com
Thursday, 24 October 2024
zacks.com
Wednesday, 23 October 2024
zacks.com
Thursday, 17 October 2024
zacks.com
zacks.com
businesswire.com
Wednesday, 9 October 2024
businesswire.com
Wednesday, 2 October 2024
zacks.com
Tuesday, 1 October 2024
zacks.com
Sunday, 29 September 2024
businesswire.com
Thursday, 26 September 2024
businesswire.com
Thursday, 12 September 2024
marketbeat.com
Monday, 2 September 2024
zacks.com
Friday, 30 August 2024
businesswire.com
  • What's the price of Alnylam Pharmaceuticals stock today?

    One share of Alnylam Pharmaceuticals stock can currently be purchased for approximately $449.12.

  • When is Alnylam Pharmaceuticals's next earnings date?

    Unfortunately, Alnylam Pharmaceuticals's (ALNY) next earnings date is currently unknown.

  • Does Alnylam Pharmaceuticals pay dividends?

    No, Alnylam Pharmaceuticals does not pay dividends.

  • How much money does Alnylam Pharmaceuticals make?

    Alnylam Pharmaceuticals has a market capitalization of 30.89B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 76.23% to 1.83B US dollars. Alnylam Pharmaceuticals made a loss 440.24M US dollars in net income (profit) last year or -$1.1 on an earnings per share basis.

  • What is Alnylam Pharmaceuticals's stock symbol?

    Alnylam Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "ALNY".

  • What is Alnylam Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Alnylam Pharmaceuticals?

    Shares of Alnylam Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Alnylam Pharmaceuticals's key executives?

    Alnylam Pharmaceuticals's management team includes the following people:

    • Dr. John M. Maraganore M.D., Ph.D. Chief Executive Officer & Executive Director(age: 62, pay: $2,070,000)
    • Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB Pres, Chief Operating Officer & Director(age: 62, pay: $1,240,000)
    • Dr. Akshay K. Vaishnaw Pres of R&D(age: 62, pay: $1,090,000)
    • Mr. Jeffrey V. Poulton M.B.A. Chief Financial Officer & Executive Vice President(age: 57, pay: $893,470)
    • Mr. Michael W. Bonney B.A. Executive Chairman(age: 67, pay: $106,250)
  • How many employees does Alnylam Pharmaceuticals have?

    As Jul 2024, Alnylam Pharmaceuticals employs 2,100 workers.

  • When Alnylam Pharmaceuticals went public?

    Alnylam Pharmaceuticals, Inc. is publicly traded company for more then 21 years since IPO on 1 Jun 2004.

  • What is Alnylam Pharmaceuticals's official website?

    The official website for Alnylam Pharmaceuticals is alnylam.com.

  • Where are Alnylam Pharmaceuticals's headquarters?

    Alnylam Pharmaceuticals is headquartered at 675 West Kendall Street, Cambridge, MA.

  • How can i contact Alnylam Pharmaceuticals?

    Alnylam Pharmaceuticals's mailing address is 675 West Kendall Street, Cambridge, MA and company can be reached via phone at +61 75518200.

  • What is Alnylam Pharmaceuticals stock forecast & price target?

    Based on 5 Wall Street analysts` predicted price targets for Alnylam Pharmaceuticals in the last 12 months, the avarage price target is $329.83. The average price target represents a -26.56% change from the last price of $449.12.

Alnylam Pharmaceuticals company profile:

Alnylam Pharmaceuticals, Inc.

alnylam.com
Exchange:

NASDAQ

Full time employees:

2,100

Industry:

Biotechnology

Sector:

Healthcare

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

675 West Kendall Street
Cambridge, MA 02142

CIK: 0001178670
ISIN: US02043Q1076
CUSIP: 02043Q107